Vericel Corp Ord Stock Today
| VCEL Stock | USD 58.14 0.38 0.66% |
Performance8 of 100
| Odds Of DistressLess than 8
|
Vericel Corp is selling for 58.14 as of the 30th of November 2024. This is a 0.66 percent increase since the beginning of the trading day. The stock's lowest day price was 57.41. Vericel Corp has only a 8 % chance of going through financial distress over the next few years but had a somewhat ok performance during the last 90 days. Equity ratings for Vericel Corp Ord are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of September 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of February 1997 | Category Healthcare | Classification Health Care |
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. The company has 49.36 M outstanding shares of which 3.7 M shares are at this time shorted by private and institutional investors with about 8.92 trading days to cover. More on Vericel Corp Ord
Moving together with Vericel Stock
| 0.91 | VTRS | Viatris | PairCorr |
| 0.64 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.61 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
Moving against Vericel Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Vericel Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Dominick Esq | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsVericel Corp can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vericel Corp's financial leverage. It provides some insight into what part of Vericel Corp's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vericel Corp Ord (VCEL) is traded on NASDAQ Exchange in USA. It is located in 64 Sidney Street, Cambridge, MA, United States, 02139 and employs 314 people. Vericel Corp is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.85 B. Vericel Corp Ord conducts business under Biotechnology sector and is part of Health Care industry. The entity has 49.36 M outstanding shares of which 3.7 M shares are at this time shorted by private and institutional investors with about 8.92 trading days to cover.
Vericel Corp Ord currently holds about 100.69 M in cash with 35.31 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.13.
Check Vericel Corp Probability Of Bankruptcy
Ownership AllocationThe majority of Vericel Corp Ord outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Vericel Corp to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Vericel Corp Ord. Please pay attention to any change in the institutional holdings of Vericel Corp Ord as this could imply that something significant has changed or is about to change at the company.
Check Vericel Ownership Details
Vericel Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Loomis, Sayles & Company Lp | 2024-06-30 | 1.1 M | |
| Bnp Paribas Investment Partners Sa | 2024-06-30 | 1 M | |
| Macquarie Group Ltd | 2024-06-30 | 1 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 910.7 K | |
| Federated Hermes Inc | 2024-09-30 | 894.7 K | |
| New York State Common Retirement Fund | 2024-09-30 | 862.7 K | |
| Rtw Investments, Llc | 2024-06-30 | 801.4 K | |
| Royal Bank Of Canada | 2024-06-30 | 762 K | |
| William Blair Investment Management, Llc | 2024-09-30 | 756.7 K | |
| Blackrock Inc | 2024-06-30 | 8.1 M | |
| Brown Capital Management, Llc | 2024-09-30 | 3.8 M |
Vericel Corp Historical Income Statement
Vericel Stock Against Markets
Vericel Corp Corporate Management
| Jonathan Siegal | VP Officer | Profile | |
| Mike Gilligan | Senior Sales | Profile | |
| Michael Halpin | Chief Officer | Profile | |
| Patrick Fowler | Senior Strategy | Profile | |
| Sean Flynn | Chief Officer | Profile | |
| Joseph Mara | CFO Treasurer | Profile | |
| MB FRCSEd | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vericel Corp Ord. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vericel Corp. If investors know Vericel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vericel Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.045 | Earnings Share 0.08 | Revenue Per Share 4.685 | Quarterly Revenue Growth 0.27 | Return On Assets (0) |
The market value of Vericel Corp Ord is measured differently than its book value, which is the value of Vericel that is recorded on the company's balance sheet. Investors also form their own opinion of Vericel Corp's value that differs from its market value or its book value, called intrinsic value, which is Vericel Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vericel Corp's market value can be influenced by many factors that don't directly affect Vericel Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vericel Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vericel Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vericel Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.